Answers are grounded in this paper and cite their sources.
To evaluate whether organ-specific dosiomics extracted from CyberKnife ® prostate SBRT plans can predict late genitourinary (GU) adverse events, and to provide clinically interpretable risk drivers using SHapley Additive exPlanations (SHAP) analysis. Eighty-seven patients with localized prostate adenocarcinoma treated with CyberKnife ® SBRT (35–36.25 Gy in five fractions) were retrospectively analyzed. Late GU adverse events were graded using the RTOG scale; the endpoint was grade 1 or higher occurring beyond 6 months (follow-up up to 5 years). PyRadiomics dosiomic features were extracted from prostate, PTV, bladder, rectum, penile bulb and a surrogate urethra model (SUM). Four models were developed on the same patients and partition, using clinical and patient-reported variables, conventional dose–volume parameters, dosiomic features, or their combination. After patient-level train/test splitting (80/20), feature filtering and LASSO selection were applied and a classifier was trained with group-aware cross-validation and class weighting. Performance was assessed on an independent hold-out test set with bootstrap confidence intervals, feature selection stability across independent training sets, and SHAP contributions related to the conventional dose–volume parameters of each structure. Late GU adverse events occurred in 17.2% of patients. The dosiomic model achieved the highest discrimination (ROC-AUC 0.92, 95% CI 0.69–1.00; PR-AUC 0.84, 95% CI 0.53–1.00, against a prevalence reference of 0.167), followed by the combined (ROC-AUC 0.90, 95% CI 0.73–1.00; PR-AUC 0.68, 95% CI 0.37–1.00), the DVH (ROC-AUC 0.86, 95% CI 0.68–1.00; PR-AUC 0.65, 95% CI 0.35–1.00) and the clinical models (ROC-AUC 0.46, 95% CI 0.22–0.70; PR-AUC 0.23, 95% CI 0.16–0.37). Adding the clinical and dose–volume blocks to the dosiomic features did not improve discrimination. Balanced accuracy was also computed (reference value 0.50): 0.80 for the dosiomic, 0.70 for the DVH and 0.43 for the clinical model. SHAP analysis identified a compact set of plausible predictors reflecting both organ geometry and dose-pattern spatial heterogeneity across bladder, urethra and prostate. An explainable dosiomics-driven approach showed encouraging discrimination for late GU adverse event prediction after CyberKnife ® prostate SBRT and provided clinically interpretable risk drivers. Multicenter validation is warranted to confirm generalizability.
No takes yet. Share an insight, caveat, or question.
Mottareale et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: